Organogenesis Holdings Inc. (ORGO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$92.1M
Cash & Equivalents
$21.1M
Quarterly Burn Rate
$309M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06618612 A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguan... OTHER Recruiting 170
NCT07510412 Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management o... OTHER Recruiting 200

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ORGO.

SEC EDGAR Filings

All SEC filings for Organogenesis Holdings Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.